Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 14;102(9):e209402.
doi: 10.1212/WNL.0000000000209402. Epub 2024 Apr 9.

Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study

Anna Dittrich  1 , Eric Westman  1 , Sara Shams  1 , Tobias Skillbäck  1 , Henrik Zetterberg  1 , Kaj Blennow  1 , Anna Zettergren  1 , Ingmar Skoog  1 , Silke Kern  1
Affiliations

Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study

Anna Dittrich et al. Neurology. .

Abstract

Objectives: To determine the prevalence of individuals with Alzheimer disease (AD) eligible for treatment with the recently FDA-approved lecanemab based on data from a population-based sample of 70-year-olds and extrapolate an estimation of individuals eligible in Europe and the United States.

Methods: Participants from the Gothenburg H70 Birth Cohort Study with clinical data, CSF-amyloid beta 42, and brain MRI analysis were evaluated for eligibility to receive lecanemab treatment according to FDA-approved recommendations, noting factors requiring special consideration. Results were used to extrapolate the number of eligible individuals in Europe and the United States using public demographic data.

Results: Thirty (10.3%) of 290 participants met the indication for treatment of whom 18 (6.2%) were eligible and did not present factors requiring special consideration. Our estimate that 6.2% of all 70-year-olds in the full cohort are eligible for treatment extrapolates to an approximation that around 5.9 million Europeans and 2.2 million US residents could be eligible.

Discussion: Information on proportion of individuals eligible for AD treatment with lecanemab in the general public is limited. We provide information on 70-year-olds in Sweden and extrapolate these data to Europe and the United States. This study opens for larger studies on this proportion and implementation of lecanemab treatment.

PubMed Disclaimer

Conflict of interest statement

A. Dittrich reports no disclosures relevant to the manuscript; E. Westman reports no disclosures relevant to the manuscript; S. Shams reports no disclosures relevant to the manuscript; T. Skillbäck reports no disclosures relevant to the manuscript; H. Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work); K. Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program; A. Zettergren reports no disclosures relevant to the manuscript; I. Skoog reports no disclosures relevant to the manuscript; S. Kern has served on the advisory board or as consultant for Optoceutics, Geras Solutions, Bioarctic, and Biogen unrelated to the present study. Go to Neurology.org/N for full disclosures.

Figures

Figure
Figure. Study Flowchart Detailing How Many Participants of the Gothenburg H70 Birth Cohort Study of 1944 Who Had Complete Data Sets on Clinical, MRI, and CSF Variables; How Many Who Met the Indication for Lecanemab Treatment; and How Many Who Did Not Present Any Factor Which Required Special Consideration for the Treatment
See this image and copyright information in PMC

References

    1. Scheltens P, Blennow K, Breteler MM, et al. . Alzheimer's disease. Lancet. 2016;388(10043):505-517. doi:10.1016/S0140-6736(15)01124-1 - DOI - PubMed
    1. Full Prescribing Information, LEQEMBI®. 7/2023. ed: U.S. Food and Drug Administration; 2023. Accessed October 7, 2023. accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf
    1. van Dyck CH, Swanson CJ, Aisen P, et al. . Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948 - DOI - PubMed
    1. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228-234. doi:10.1016/S1474-4422(06)70355-6 - DOI - PubMed
    1. Rydberg Sterner T, Ahlner F, Blennow K, et al. . The Gothenburg H70 Birth cohort study 2014-16: design, methods and study population. Eur J Epidemiol. 2019;34(2):191-209. doi:10.1007/s10654-018-0459-8 - DOI - PMC - PubMed